CTOs on the Move

Akero Therapeutics

www.akerotx.com

 
Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.akerotx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.487.6488

Executives

Name Title Contact Details
Scott Gangloff
Chief Technology Officer Profile

Funding

Akero Therapeutics raised $65M on 06/25/2018
Akero Therapeutics raised $70M on 12/12/2018

Similar Companies

Appili Therapeutics

Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development.

Senti Bio

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.

Trinity Biomedical

Trinity Biomedical is a Menomonee Falls, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encore Rehabilitation

Encore Rehabilitation is a Berkley, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Life Molecular Imaging

Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit https://life-mi.com. https://neuraceq.com/wp-content/uploads/USPI-DOC-1118-v5.1-May-2023.pdf